secwatch.observer — SEC 8-K summary
======================================

Issuer:     GoodRx Holdings, Inc. (GDRX)
CIK:        0001809519
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001809519-25-000035
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GoodRx reports Q4 revenue $198.6M, net income $6.7M; full-year revenue $792.3M, Adj. EBITDA $260.2M
--------------------------------------------------------------------------------

- Q4 2024 revenue of $198.6M, net income $6.7M (3.4% margin), Adjusted EBITDA $67.1M (33.8% margin).
- Full year 2024 revenue $792.3M, net income $16.4M (2.1% margin), Adjusted EBITDA $260.2M (32.8% margin).
- Q4 operating cash flow $44.7M, full-year $183.9M; over 7 million prescription consumers at quarter end.
- Results described as substantially in-line with previous guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1809519/000180951925000035/0001809519-25-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1809519/000180951925000035/gdrx-20250227.htm
  HTML page:      https://secwatch.observer/filing/0001809519-25-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer